logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Nerve Stimulator Market, By Type (Spinal Cord Stimulator (SCS), Vagus Nerve Stimulator (VNS), Deep Brain Stimulator (DBS)) By Application (Parkinson’s disease, Epilepsy, Chronic Pain, and Depression) By End User (Trauma Centers, Hospital & Clinics Ambulatory Surgical Centers) opportunities and forecast 2020-2027

  • DLR2218
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

The nerve stimulation is the process that utilizes an electrical current or electrical impulse for the treatment of chronic pain. The process has two types of electrical stimulation techniques are Peripheral nerve stimulation (PNS) and spinal cord stimulation (SCS).

The major driving factors of the global nerve stimulators market are; growing number of cases related to various chronic health disorders, increasing technological development, rising aged population around the globe, improvement in the refunding policies, increasing demand for minimally invasive procedures. However some factors restraining the market growth include high cost of the treatment and lack of skilled medical professionals.

Segment Overview

The growing prevalence of minimally invasive procedures around the globe is leading to the market development. However, high expense of treatment and lack of experienced and skilled doctors may restrict the progress of the market during the estimated period. The global market is segmented on the basis of type, application, end-users, and region. Based on type, the market is classified into spinal cord stimulator (SCS), vagus nerve stimulator (VNS), and deep brain stimulator (DBS).

Based on its end -users, the market is segmented as ambulatory surgical centers, hospital and clinics, and trauma centers.

Regional Overview

The North America region commanded the major market share in 2019 due to growing number of cases related to chronic disorders, technological advancements in the country such as U.S., increasing spending on the healthcare sector, and presence of major players in the market.

The therapy is one of the best methods from treating various health problems such as joint or bone issues which happens in case of osteoarthritis or fibromyalgia, neck pain, overactive bladder, neurological disorders, low back pain, and others. The rising rate of endless medical issues, expanding geriatric populace, innovative upgrades, and improvement in repayment policies are the major variables driving the market growth.

Competitor overview

Key companies functional in the global nerve stimulator market are Deep Dive, Cerbomed GmbH, NERVANA LLC, LivaNova LLC, ReShape Lifesciences Inc., New product developments and product enhancements are the key growth strategies by the major companies. Furthermore the major players are focused on Strategic collaborations to increase geographical outreach to increase their market share.

Key Players
  1. NeuroPace, Inc.
  2. Boston Scientific Corporation
  3. Aleva Neurotherapeutics SA
  4. Cochlear Ltd.
  5. Cyberonics, Inc.
  6. Medtronic
  7. St Jude Medical, Inc.
  8. LivaNova LLC,
  9. ReShape Lifesciences Inc
  10. Parasym Health

Market Segmentation

By Type
  • Spinal Cord Stimulator (SCS)
  • Vagus Nerve Stimulator (VNS)
  • Deep Brain Stimulator (DBS)
By Application
  • Parkinson’s disease,
  • Epilepsy,
  • Chronic Pain,
  • Depression
By End User
  • Trauma Centres,
  • Hospital & Clinics
  • Ambulatory Surgical Centres
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 11

    2 Market Introduction 13

    • 2.1 Research Objective 13
    • 2.2 Assumptions & Limitations 13
      • 2.2.1 Assumptions 13
      • 2.2.2 Limitations 13

    3 Research Methodology 15

    • 3.1 Research Process 15
    • 3.2 Primary Research 16
    • 3.3 Secondary Research 16
    • 3.4 Market Size Estimation 17

    4 Market Dynamics 19

    • 4.1 Introduction 19
    • 4.2 Drivers 20
      • 4.2.1 Rising incidence of chronic health problems (Impact weightage: 35%) 20
      • 4.2.2 Technological improvements (Impact weightage: 35%) 21
      • 4.2.3 Increasing geriatric population (Impact weightage: 20%) 22
      • 4.2.4 Improved reimbursement policies in developed countries (Impact weightage: 10%) 23
    • 4.3 Restrains 24
      • 4.3.1 Lack of skilled or trained physicians (Impact weightage: 60%) 24
      • 4.3.2 High cost of nerve stimulation therapy (Impact weightage: 40%) 25
    • 4.4 Opportunity 26
      • 4.4.1 Increasing popularity of minimally invasive procedures across the globe 26
    • 4.5 Macroeconomic Indicators 26

    5 Market Factor Analysis 27

    • 5.1 Porter’s Five Forces Model 27
      • 5.1.1 Bargaining Power of Suppliers 27
      • 5.1.2 Bargaining Power of Buyers 28
      • 5.1.3 Threat on New Entrants 28
      • 5.1.4 Threat of Substitutes 28
      • 5.1.5 Intensity of Rivalry 28
    • 5.2 Value Chain Analysis 29
      • 5.2.1 R&D and Designing 29
      • 5.2.2 Manufacturing 29
      • 5.2.3 Distribution & Sales 30
      • 5.2.4 Post-sales Monitoring 30
    • 5.3 Demand & Supply: Gap Analysis 31
    • 5.4 Pricing Analysis 31

    6 Global Nerve Stimulator Market by Type 32

    • 6.1 Introduction 32
    • 6.2 Deep Brain Stimulator (DBS) 33
    • 6.3 Vagus Nerve Stimulator (VNS) 34
    • 6.4 Spinal Cord Stimulator (SCS) 34

    7 Global Nerve Stimulator Market by Applications 35

    • 7.1 Introduction 35
    • 7.2 Chronic Pain 36
    • 7.3 Depression 37
    • 7.4 Dystonia 37
    • 7.5 Epilepsy 38
    • 7.6 Parkinson’s Disease 38

    8 Global Nerve Stimulator Market by End Users 39

    • 8.1 Introduction 39
    • 8.2 Ambulatory Surgical Centers 40
    • 8.3 Hospital & Clinics 41
    • 8.4 Trauma Centers 41

    9 Global Nerve Stimulator Market by Regions 42

    • 9.1 Introduction 42
    • 9.2 Americas 43
      • 9.2.1 North America 46
        • 9.2.1.1 US 47
        • 9.2.1.2 Canada 49
      • 9.2.2 South America 50
    • 9.3 Europe 52
      • 9.3.1 Western Germany 54
        • 9.3.1.1 Germany 56
        • 9.3.1.2 France 57
        • 9.3.1.3 Italy 59
        • 9.3.1.4 Spain 60
        • 9.3.1.5 UK 62
        • 9.3.1.6 Rest of Western Europe 63
      • 9.3.2 Eastern Europe 65
    • 9.4 Asia Pacific 67
      • 9.4.1 China 69
      • 9.4.2 India 71
      • 9.4.3 Japan 72
      • 9.4.4 South Korea 74
      • 9.4.5 Australia 75
      • 9.4.6 Rest of Asia Pacific 77
    • 9.5 Middle East & Africa 79
      • 9.5.1 UAE 81
      • 9.5.2 Saudi Arabia 83
      • 9.5.3 Oman 84
      • 9.5.4 Kuwait 86
      • 9.5.5 Qatar 87
      • 9.5.6 Rest of Middle East & Africa 89

    10 Competitive Landscape 91

    • 10.1 Introduction 91

    11 Company Profile 92

    • 11.1 Boston Scientific Corporation 92
      • 11.1.1 Company Overview 92
      • 11.1.2 Financials 92
      • 11.1.3 Products 92
      • 11.1.4 Strategy 92
      • 11.1.5 Key Developments 92
    • 11.2 Cochlear ltd. 93
      • 11.2.1 Company Overview 93
      • 11.2.2 Financials 93
      • 11.2.3 Products 93
      • 11.2.4 Strategy 93
      • 11.2.5 Key Developments 93
    • 11.3 Medtronic 94
      • 11.3.1 Company Overview 94
      • 11.3.2 Financials 94
      • 11.3.3 Products 94
      • 11.3.4 Strategy 94
      • 11.3.5 Key Developments 94
    • 11.4 St Jude Medical, Inc. 95
      • 11.4.1 Company Overview 95
      • 11.4.2 Financials 95
      • 11.4.3 Products 95
      • 11.4.4 Strategy 95
      • 11.4.5 Key Developments 95
    • 11.5 Cyberonics, Inc. 96
      • 11.5.1 Company Overview 96
      • 11.5.2 Financials 96
      • 11.5.3 Products 96
      • 11.5.4 Strategy 96
      • 11.5.5 Key Developments 96
    • 11.6 Aleva Neurotherapeutics SA 97
      • 11.6.1 Company Overview 97
      • 11.6.2 Financials 97
      • 11.6.3 Products 97
      • 11.6.4 Strategy 97
      • 11.6.5 Key Developments 97
    • 11.7 NeuroPace, Inc. 98
      • 11.7.1 Company Overview 98
      • 11.7.2 Financials 98
      • 11.7.3 Products 98
      • 11.7.4 Strategy 98
      • 11.7.5 Key Developments 98

    12 Conclusion 99

    • 12.1 Key Findings 99
      • 12.1.1 From CEO’s View Point 99
    • 12.2 Key Companies to Watch 99

    13 Appendix 100

    Report You Might be Interested